Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15N5O2 |
Molecular Weight | 213.237 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NNC1=NN=C(C=C1)N(CCO)CCO
InChI
InChIKey=POFDNYKJHWKGDU-UHFFFAOYSA-N
InChI=1S/C8H15N5O2/c9-10-7-1-2-8(12-11-7)13(3-5-14)4-6-15/h1-2,14-15H,3-6,9H2,(H,10,11)
Molecular Formula | C8H15N5O2 |
Molecular Weight | 213.237 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Oxdralazine is a peripheral vasodilator that was studied for patients with severe essential hypertension. The clinical trial has shown that at the end of the third month 25 patients on the triple regimen (chlorthalidone plus oxdralazine plus propranolol) achieved a stable diastolic blood pressure of 90 mm Hg or less. However, information about the further development of this drug is not available.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Onthe pharmacology of 3-hydrazino-6-(N,N-bis(2-hydroxyethyl)amino)-pyridazine-dihydrochloride (L 6150). | 1973 Nov |
|
A comparative study of the hemodynamic effects of single intravenous doses of 3-hydrazino-6-[N,N-bis-(2-hydroxyethyl)-amino]-pyridazine-dihydrochloride and hydralazine. | 1976 |
|
Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. | 1976 |
|
Clinical and haemodynamic study of a new vasodilator drug L6150 (3-[bis-(2-hydroxyethyl)amino]-6-hydrazinopyridazine) in man. | 1976 Dec |
|
Synthesis of three metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine. A new rearrangement of 3-[1-methylethyliden)hydrazino] derivative. | 1978 Aug |
|
Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats. | 1978 Jun |
|
Disposition and metabolism of 3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino] pyridazine dihydrochloride in man. | 1979 |
|
Long-term study of oxdralazine in hypertensive patients. | 1979 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7379444
Oxdralazine was given orally in doses of 15 to 30 mg to 7 subjects with hypertension
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:02:06 GMT 2023
by
admin
on
Sat Dec 16 18:02:06 GMT 2023
|
Record UNII |
K6SU81C9V1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
28434
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
SUB09511MIG
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
C80882
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104718
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
DTXSID30169351
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
100000083055
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
C006198
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
K6SU81C9V1
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
17259-75-5
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY | |||
|
4322
Created by
admin on Sat Dec 16 18:02:06 GMT 2023 , Edited by admin on Sat Dec 16 18:02:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |